Recently, Hong Kong Pharma Digital Technology Holdings Limited (hereinafter referred to as "HK Pharma Digital Tech"), a comprehensive pharmaceutical cross-border e-commerce supply chain service provider from Hong Kong, has successfully listed on the U.S. NASDAQ, with its stock ticker being HKPD. It had initially planned to complete an IPO on the NASDAQ. It previously filed confidentially with the U.S. Securities and Exchange Commission (SEC) on March 29, 2024, and publicly disclosed its prospectus on October 29 of the same year. HK Pharma Digital Tech offered 1 million shares at $4 per share (excluding 403,685 secondary shares sold by existing shareholders), raising $4 million. Link to HK Pharma Digital Tech’s prospectus: https://www.sec.gov/Archives/edgar/data/2007702/000121390025003870/ea0227659-424b4_hongkong.htm HK Pharma Digital Tech, based in Hong Kong, is a comprehensive pharmaceutical cross-border e-commerce supply chain service provider that mainly provides two categories of services: (i) Over-the-counter (OTC) drug cross-border e-commerce supply chain services through its Hong Kong subsidiary United Cross-Border Logistics Co., Ltd. (hereinafter referred to as "United Cross-Border"); and (ii) OTC drug cross-border procurement and distribution services through its Hong Kong subsidiary Vimark Technology Supply Co., Ltd. By cooperating with OTC drug suppliers, logistics companies and merchants on Chinese e-commerce platforms, United Cross-Border provides convenient one-stop solutions for Chinese mainland customers to purchase OTC drugs outside the Chinese mainland. The comprehensive services provided by United Cross-Border include pre-consultation, product information review, procurement of overseas OTC drugs, application for product registration with the Hong Kong Department of Health, acquisition of import and export licenses, product storage and packaging, as well as arranging logistics and door-to-door delivery services for customers. As of the closing on Friday (January 17, 2025), HK Pharma Digital Tech (HKPD) closed at $2.75 per share, a 31.25% drop from the IPO offering price, with a current market value of approximately $30.25 million. © 2021 Meishun (Hong Kong) Management Consulting Co., Ltd. and Meishun (Hangzhou) Management Consulting Co., Ltd. All rights reserved. Meishun Meiyin (Hangzhou) Consulting Management Co., Ltd. is a domestic subsidiary of Hong Kong Meishun Management Consulting Co., Ltd. under the same actual controller. Both companies are under the same actual controller, and both are managed under the framework of "One China". The companies comply with the laws of Hong Kong and mainland China.